SHLD1

C20orf196 is located on the short arm of chromosome 20 at 20p12.3, from base pairs 5,750,286 to 5,864,407 on the direct strand.[5] It contains 11 exons.[7]

Its aliases are RINN3[6] and SHLD1.

C20orf196 produces 9 different mRNAs, with 7 alternatively spliced variants and 2 unspliced forms.[7] There are 3 probable alternative promoters, 3 non-overlapping alternative last exons, and 2 alternative polyadenylation sites.[7] The mRNAs differ by the truncation of the 5' end, truncation of the 3' end, presence or absence of 2 cassette exons, and overlapping exons with different boundaries.[7]

C20orf196 has six splice isoforms.[7]

The promoter region is within bases 5749286 to 5750555, totaling 1270 base pairs.[5] The transcription start site is located within bases 5750382 and 5750409, totaling 28 base pairs.[5]

NCBI GEO Human Tissue Expression Profile for C20orf196.

RNA-Seq analysis has shown ubiquitous expression of c20orf196 in 26 human tissues: adrenal, appendix, bone marrow, brain, colon, duodenum, endometrium, esophagus, fat, gall bladder, heart, kidney, liver, lung, lymph node, ovary, pancreas, placenta, prostate, salivary gland, skin, small intestine, spleen, stomach, testis, thyroid, and urinary bladder.[5] The highest C20orf196 mRNA levels were found in the lymph node, tonsil, thyroid, adrenal gland, prostate, pharynx, parathyroid, connective tissue, and bone marrow.[8]

C20orf196 was found to be expressed in soft tissue/muscle tissue tumors, lymphoma tumors, and pancreatic tumors.[9] C20orf196 representation was biased toward the fetal developmental stage.[9] EBI expression data showed high expression of C20orf196 in the diencephalon and cerebral cortex in the developing brain.[9]

The most common transcript encodes a protein that is 205 amino acids long with a molecular mass of 23 kDa.[10] It has a predicted isoelectric point of 4.72.[11] It is predicted to have a half-life around 30 hours.[12] C20orf196 contains 19 positive residues (9.3%), 32 negative residues (15.6%), and 46 hydrophobic residues (22.4%).[13]

C20orf196 is predicted to localize in the nucleus.[7]

C20orf196 contains one domain, DUF4521, which arose in Amniote.[5] DUF4521 spans from amino acid 3 to 201.[5] Several regions of this domain are conserved in c20orf196 orthologs found in mammals, amphibians, and fish. The proteins of this family are functionally uncharacterized.

There are many phosphorylation sites targeted by unspecified serine kinases.[14] C20orf196 is predicted to have one SUMOylation site at amino acid 203 and one N-glycosylation site at amino acid 69.[15][16] C20orf196 is predicted to have two ubiquitination sites at amino acids 84 and 139.[17]

Several modeling programs predicted a secondary structure containing alpha helix, beta sheet, and coil regions.[18][19] CFSSP has predicted that C20orf196 secondary structure is 57.1% alpha helices, 48.8% beta strands, and 16.6% beta turns.[20]

Several databases citing yeast two-hybrid screenings have found C20orf196 to interact with PRMT1, QARS, MAD2L2, and CUL3.[21][22][23][24] C20orf196 functionally interacts with REV7, SHLD2, and SHLD3 in the shieldin complex within the DNA repair network.[6]

C20orf196 gene orthologs are found in species including mammals, birds, reptiles, and amphibians.[6][25] C20orf196 has distant orthologs in bony fish and cartilaginous fish.[6][25] There are no invertebrate orthologs.[6] Orthologs are found in 163 organisms.[5]

There are no paralogs in humans.[5]

Figure illustrating the evolution rate for C20orf196 in twenty orthologs as compared to the fast-evolving protein, fibrinogen, and slow-evolving protein, cytochrome C.

C20orf196 has a high protein sequence divergence rate. It is a fast evolving protein. It evolves faster than fibrinogen, as seen in the figure to the right.